ASH is heading to San Diego!
Every year we eagerly await the American Society of Hematology (ASH) late breaking abstract reveal. They can be sublime or disappointing, depending on the data available.
This year the conference is back in sunny San Diego.
We’ve already created some order from the chaos of the initial data dump and highlighted some key abstracts to watch out for in our first Preview post in the ASH18 series.
This time we look at what’s in store and – more importantly – what can we learn about the chosen LBA selections? What sort of caveats do we need to be mindful of?
It turns out that that’s quite a bit to think about…
To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
ASH 2015 LBA Session
The annual meeting of the American Society of Hematology (ASH) has a few quirks compared to other meetings. One of these is that all the “Late Breakers” are presented together on the last morning of the meeting.
It’s a rather unfortunate time given many have already headed back to their busy clinics or left for SABCS in San Antonio and ‘late breakers’ by definition, often offer new data that’s really noteworthy.
The result can also be a bit of a hodgepodge session that you have sit to listen through to get to those presentations you really want to hear.
At ASH this year there were two late breakers on new treatment options for CLL patients with a 17p deletion (Del17p). This is a pretty challenging group to treat. Although ibrutinib is indicated for this patient group, many sadly relapse. There’s an unmet medical need for new treatment options. At ASH we heard data for idelalisib (PI3K-delta) and venetoclax (Bcl2).
After the session, I briefly spoke with Dr Kanti Rai (New York) for his reaction to the data. Dr Rai (pictured below) received the 2014 Wallace H. Coulter Award for Lifetime Achievement in Hematology.
Dr Kanti Rai receives 2014 ASH Lifetime Achievement Award
Subscribers can login in or you can purchase access.